Financial Times | June 1, 2021
Matthew Kavanagh, the director of the Global Health Policy & Politics Initiative at Georgetown university, said the timing of international deliveries was the bigger issue.
“The problem is that companies are not providing sufficient rapid supply of vaccines to African countries,” he said. “The idea that African countries should use the leftovers of high-income countries, including expired doses, is not only deeply unethical but a recipe for vaccine hesitancy.”